BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2017 9:25:57 AM | Browse: 1133 | Download: 2130
 |
Received |
|
2017-02-07 17:34 |
|
Peer-Review Started |
|
2017-02-08 13:43 |
|
To Make the First Decision |
|
2017-03-16 13:18 |
|
Return for Revision |
|
2017-03-22 09:27 |
|
Revised |
|
2017-03-29 02:34 |
|
Second Decision |
|
2017-05-04 17:49 |
|
Accepted by Journal Editor-in-Chief |
|
2017-05-04 20:04 |
|
Accepted by Executive Editor-in-Chief |
|
2017-05-09 17:12 |
|
Articles in Press |
|
2017-05-09 17:12 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-06-06 08:48 |
|
Publish the Manuscript Online |
|
2017-06-14 09:25 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tomas Koller, Martina Galambosova, Simona Filakovska, Michaela Kubincová, Tibor Hlavatý, Anna Krajčovičová, Jozef Tóth and Juraj Payer |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tomas Koller, MD, PhD, Associate Professor, 5th Department of Internal Medicine, Gastroenterology and Hepatology, Comenius University in Bratislava Faculty of Medicine, University Hospital Bratislava Ruzinov, Ruzinovska 6, 82606 Bratislava, Slovakia. tomas.koller@ru.unb.sk |
| Key Words |
Drug-induced liver injury; Risk factors; Inflammatory bowel disease; Infliximab; Adalimumab; Azathioprine |
| Core Tip |
We evaluated liver injury in consecutive inflammatory bowel disease (IBD) patients followed for one year in whom aminotransferase activities (AT) were measured at baseline and at 3 mo intervals. We found AT elevations frequently, but they were mostly mild and transient. Even persisting abnormalities had rarely an effect on IBD management. However, ALT elevations and cholestasis appeared more commonly among patients treated with infliximab (ALT) or azathioprine (cholestasis). This finding points to their potential for hepatotoxicity and the need for regular AT monitoring. |
| Publish Date |
2017-06-14 09:25 |
| Citation |
Koller T, Galambosova M, Filakovska S, Kubincova M, Hlavaty T, Toth J, Krajcovicova A, Payer J. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study. World J Gastroenterol 2017; 23(22): 4102-4111 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i22/4102.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i22.4102 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
